Year-end Report January – December 2011

Feb 16, 2012 08:30 (CET)
· Laquinimod – a clinical trial is planned prior to filing an NDA in the US
                    
· TASQ         – an investigator-sponsored Phase I clinical trial launched
                    – enrolment of patients for Phase III trial proceeding according to plan
 
· ANYARA    – Phase III trial continuing according to plan

· 57-57          – a clinical trial in systemic sclerosis/scleroderma initiated

· ISI              – project is proceeding as planned

· RhuDex®    – a Phase I clinical formulation study launched

· Focusing of the operation; notice of termination of employment to 25 staff members

· Net sales SEK 234.6 M (11.4)

· Operating loss SEK 100.9 M (Loss: 229.0)

· Loss after tax SEK 94,5 M (Loss: 221.1)

· Loss per share for the period was SEK 1.38 (Loss: 3.38)
 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95    

Hans Kolam     
CFO     
Tel +46 (0)46-19 20 44     

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00 
Fax +46 (0)46-19 11 00

This report is also available at www.activebiotech.com   

Year-end Report January – December 2011

—
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1586221